M Kaufman - Multiple sclerosis (Houndmills, Basingstoke, England), 1997 - ncbi.nlm.nih.gov 1: Mult Scler. 1997 Aug;3(4):248-9. Treatment of multiple sclerosis with
high-dose corticosteroids may prolong the prothrombin time ... Cited by 8 - Related articles - All 3 versions
N Costedoat-Chalumeau, Z Amoura, B … - Revue de Medecine Interne, 2001 - Elsevier Premièrement, un marqueur fiable de l'activité anticoagulante a été
développé, conduisant à l'abandon du taux de prothrombine au profit de l'INR
dont les résultats sont standardisés [3]. La reproductibilité de cette ... Related articles - All 2 versions
I Mahe, N Bertrand, L Drouet, G Simoneau, E … - British journal of clinical pharmacology, 2005 - pubmedcentral.nih.gov In a prospective double-blind, cross-over, placebo-controlled study, 11 patients
on stable warfarin therapy received in random order two 14-day regimens of
paracetamol 4 g day −1 or placebo, with a 14-day or more wash-out period ... Cited by 30 - Related articles - All 6 versions
- ►nih.gov [PDF] JB Chatterjea, L Salomon - British Medical Journal, 1954 - pubmedcentral.nih.gov Prognosis and Treatment The case mortality in the present series was 10%° (the
same as in Ford's (1928) series); delirium andcoma were sudden in the fatal case
and continued to the end five days later. Complicating features were ... Cited by 17 - Related articles - All 3 versions
[CITATION] The optimal diagnostic management strategy in patients with suspected deep vein …
G Aymard, M Legrand, E Comets, F Mentre, B … - Journal of Chromatography B: Biomedical Sciences and …, 1998 - Elsevier A new high-performance liquid chromatographic (HPLC) assay without any
extraction procedure was developed for the quantification of fluindione in
plasma using a 100-μl sample volume and coumarin as the internal standard. ... Cited by 4 - Related articles - All 4 versions
RP Riechelmann, C Zimmermann, SN Chin, L … - Journal of pain and symptom management, 2008 - Elsevier Cancer patients at the end of life often take many medications and are at risk
for drug interactions. The purpose of this study was to describe the
epidemiology of potential drug interactions in cancer patients receiving ... Cited by 5 - Related articles - All 19 versions
AA Sasahara, CC St Martin, J Henkin, WM … - Hematology/oncology clinics of North America, 1992 - ncbi.nlm.nih.gov This article reviews the different thrombolytic agents currently available and
the different mechanisms by which they activate the body's fibrinolytic system.
The discussion is confined to the approach to the patient with venous ... Cited by 6 - Related articles - BL Direct - All 2 versions
